HR
CABA icon

Howe & Rusling’s Cabaletta Bio CABA Stock Holding History

Howe & Rusling’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-100
Closed – – 1069
2022
Q2 		$0 Buy
+100
New +$141 ﹤0.01% 1067

Other funds holding CABA

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Howe & Rusling's CABA Position: Q3 2022 in Review

Howe & Rusling sold out of Cabaletta Bio (CABA) in Q3 2022, closing a stake of 100 shares.

Howe & Rusling first reported a position in CABA in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 54 funds tracked by Wall St. Rank hold CABA as of Q3 2022.

  • Howe & Rusling reported no remaining Cabaletta Bio position as of Q3 2022 after selling out during the quarter.
  • Howe & Rusling sold 100 Cabaletta Bio shares in Q3 2022.
  • Howe & Rusling first reported a position in Cabaletta Bio in Q2 2022 and held it in 1 quarter.
  • Howe & Rusling's Cabaletta Bio position peaked at $0 in Q2 2022.
  • 54 funds tracked by Wall St. Rank held Cabaletta Bio as of Q3 2022.

Based on Howe & Rusling's 13F filing for Q3 2022, filed 14 Nov 2022.